ALLO vs C · rev $22.0K vs P/E 16, rev $85.22B
Allogene Therapeutics Inc (ALLO) versus Citigroup Inc. (C) — a side-by-side from cached financials, not a winner call.
Allogene Therapeutics Inc (ALLO) is a biotechnology company listed on US.
Citigroup Inc. (C) is a banks - diversified company listed on US.
Latest reported ALLO revenue for 2024-12-31 was $22.0K. Net income was -$257.6M. Revenue was down 76.8% from 2023-12-31 to 2024-12-31. ALLO currently screens at market cap $258.1M.
Latest reported C revenue for 2025-12-31 was $85.22B. Net income was $14.31B. Revenue was up 5.0% from 2024-12-31 to 2025-12-31. C currently screens at market cap $214.73B and trailing P/E 15.5.
ALLO currently screens at market cap $258.1M. C currently screens at market cap $214.73B and trailing P/E 15.5.
Not investment advice. Open the ALLO and C stock pages for the full models.
Not investment advice.